Morgan Stanley Maintains Overweight on Gilead Sciences, Lowers Price Target to $165

Benzinga · 1d ago
Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight and lowers the price target from $166 to $165.